Karen Lightning-Jones, Integrated Franchise Leader at Roche Pipeline, speaks to pharmaphorum’s Linda Banks in Deep Dive: Digital II about how the company is applying data management and digital tools in the real world, and advancing genomic testing to improve treatment and outcomes in cancer.
The FDA has approved Johnson & Johnson’s next generation prostate cancer drug, apalutamide in an early but tough to treat form of prostate cancer that has not spread.
Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it be about repeat the trick with a new drug that stimulates natural kill
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
